Journal of Clinical Endocrinology & Metabolism, Vol 79, 960-964, Copyright © 1994 by Endocrine Society

ARTICLES

Anti-mullerian hormone in children with androgen insensitivity

R Rey, F Mebarki, MG Forest, I Mowszowicz, RL Cate, Y Morel, JL Chaussain and N Josso
Unite de Recherches sur l'Endocrinologie du Developpement (INSERM), Ecole Normale Superieure, Montrouge, France.

Anti-Mullerian hormone (AMH), also called Mullerian inhibiting substance or factor, is secreted in high amounts by the immature Sertoli cell; it is negatively regulated by testosterone at puberty. In the present study, we measured serum AMH in 20 patients with defects of androgen synthesis or action: 9 with complete androgen insensitivity syndrome, 9 with a partial form, 1 patient with 3 beta-hydroxysteroid dehydrogenase deficiency, and 1 with Leydig cell agenesis. AMH was also determined in 15 control patients with idiopathic male pseudohermaphroditism. The serum AMH concentration was elevated in all testosterone-insensitive or -deficient patients compared with control levels during the first year of life. From 1 yr of age to the onset of puberty, serum AMH levels in patients with androgen insensitivity returned to normal values, but after pubertal development began, AMH levels again rose to extremely high levels in the complete androgen insensitivity syndrome. These results suggest that AMH is negatively regulated by testosterone not only at puberty, but also during the postnatal period. An elevation of serum AMH appears to be an interesting marker of androgen resistance or defect of androgen production in sexually ambiguous male infants.

This article has been cited by other articles:

				P J O'Shaughnessy, L Hu, and P J Baker Effect of germ cell depletion on levels of specific mRNA transcripts in mouse Sertoli cells and Leydig cells Reproduction, June 1, 2008; 135(6): 839 - 850. [Abstract] [Full Text] [PDF]

				M. J. Goedken, R. L. Kerlin, and D. Morton Spontaneous and Age-Related Testicular Findings in Beagle Dogs Toxicol Pathol, April 1, 2008; 36(3): 465 - 471. [Abstract] [Full Text] [PDF]

				R. A. Rey, E. Codner, G. Iniguez, P. Bedecarras, R. Trigo, C. Okuma, S. Gottlieb, I. Bergada, S. M. Campo, and F. G. Cassorla Low Risk of Impaired Testicular Sertoli and Leydig Cell Functions in Boys with Isolated Hypospadias J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6035 - 6040. [Abstract] [Full Text] [PDF]

				J. Young, P. Chanson, S. Salenave, M. Noel, S. Brailly, M. O'Flaherty, G. Schaison, and R. Rey Testicular Anti-Mullerian Hormone Secretion Is Stimulated by Recombinant Human FSH in Patients with Congenital Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 724 - 728. [Abstract] [Full Text] [PDF]

				C. Chang, Y.-T. Chen, S.-D. Yeh, Q. Xu, R.-S. Wang, F. Guillou, H. Lardy, and S. Yeh Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells PNAS, May 4, 2004; 101(18): 6876 - 6881. [Abstract] [Full Text] [PDF]

				D. T. MacLaughlin and P. K. Donahoe Sex Determination and Differentiation N. Engl. J. Med., January 22, 2004; 350(4): 367 - 378. [Full Text] [PDF]

				C. Y. Hong, J. H. Park, K. H. Seo, J.-M. Kim, S. Y. Im, J. W. Lee, H.-S. Choi, and K. Lee Expression of MIS in the Testis Is Downregulated by Tumor Necrosis Factor Alpha through the Negative Regulation of SF-1 Transactivation by NF-{kappa}B Mol. Cell. Biol., September 1, 2003; 23(17): 6000 - 6012. [Abstract] [Full Text] [PDF]

				C. Lukas-Croisier, C. Lasala, J. Nicaud, P. Bedecarras, T. R. Kumar, M. Dutertre, M. M. Matzuk, J.-Y. Picard, N. Josso, and R. Rey Follicle-Stimulating Hormone Increases Testicular Anti-Mullerian Hormone (AMH) Production through Sertoli Cell Proliferation and a Nonclassical Cyclic Adenosine 5'-Monophosphate-Mediated Activation of the AMH Gene Mol. Endocrinol., April 1, 2003; 17(4): 550 - 561. [Abstract] [Full Text] [PDF]

				J. Teixeira, S. Maheswaran, and P. K. Donahoe Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications Endocr. Rev., October 1, 2001; 22(5): 657 - 674. [Abstract] [Full Text] [PDF]

				W.-Q. Long, V. Ranchin, P. Pautier, C. Belville, P. Denizot, H. Cailla, C. Lhommé, J.-Y. Picard, J.-M. Bidart, and R. Rey Detection of Minimal Levels of Serum Anti-Mullerian Hormone during Follow-Up of Patients with Ovarian Granulosa Cell Tumor by Means of a Highly Sensitive Enzyme-Linked Immunosorbent Assay J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 540 - 544. [Abstract] [Full Text]

				E. Rajpert-De Meyts, N. Jorgensen, N. Gram, J. Muller, R. L. Cate, and N. E. Skakkebak Expression of Anti-Mullerian Hormone during Normal and Pathological Gonadal Development: Association with Differentiation of Sertoli and Granulosa Cells J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3836 - 3844. [Abstract] [Full Text] [PDF]

				J. Young, R. Rey, B. Couzinet, P. Chanson, N. Josso, and G. Schaison Antimullerian Hormone in Patients with Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2696 - 2699. [Abstract] [Full Text]

				M. M. Lee, P. K. Donahoe, B. L. Silverman, T. Hasegawa, Y. Hasegawa, M. L. Gustafson, Y. Chang, and D. T. MacLaughlin Measurements of Serum Mullerian Inhibiting Substance in the Evaluation of Children with Nonpalpable Gonads N. Engl. J. Med., May 22, 1997; 336(21): 1480 - 1486. [Abstract] [Full Text] [PDF]

				M. G. Forest Serum Mullerian Inhibiting Substance Assay -- A New Diagnostic Test for Disorders of Gonadal Development N. Engl. J. Med., May 22, 1997; 336(21): 1519 - 1521. [Full Text]